Comparisons of efficacy and safety of 400 or 800 ml bacterial count fecal microbiota transplantation in the treatment of recurrent hepatic encephalopathy: a multicenter prospective randomized controlled trial in China

Pengfei Zou(National Center for Nanoscience and Technology), Hainv Gao, Yu‐Chen Fan(Qilu Hospital of Shandong University), Yubao Zheng(Sun Yat-sen University), Hai Huang(Zhejiang Chinese Medical University), Wei‐Zen Sun(Cathay General Hospital), Qingjing Ru(Zhejiang Chinese Medical University), Zhifeng Qiu(Baotou Central Hospital), Qiaofei Jin(Hangzhou Xixi hospital), Qifu Li(Hainan Medical University), Richeng Mao(Fudan University), Suping Ma(First Affiliated Hospital of Henan University), Dan Zhao(Zhengzhou People's Hospital), Hui Shao(Tulane University), Lin Qing(HOPE Clinic), Guoqiang Zhang(Johnson & Johnson (United States)), Jinfeng Liu(First Affiliated Hospital of Xi'an Jiaotong University), Qiang Chen(Alexza Pharmaceuticals (United States)), Hui Wang(Shanghai Jiao Tong University), Feng Ding(University of Calgary), Yongping Zhang(Xinjiang Medical University), Kai Wang(Artificial Intelligence Research Institute), Tao Wu(The Graduate Center, CUNY), Zhiping Qian(Shanghai Public Health Clinical Center), Jiawei Geng(Zhejiang University), Li-ying You(The First Hospital of Kunming), Yun-Song Qian(Ningbo No. 2 Hospital), Zhaowei Tong(Huzhou Central Hospital), Xiao Liu(Qingdao University), Xiaoting Zhang, Fang Wang(Hubei University of Arts and Science), Jiaojian Lv(Lishui City People's Hospital), Xin Wang(Capital Medical University), Yunjiao Bi(Zhejiang Chinese Medical University)
Trials
November 27, 2024
Cited by 2


Related Papers